drugset / Trial / NCT03469271

Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients

NCT03469271

Phase 4 Completed 63 enrolled Mayo Clinic Andersen Foundation · collab
RandomizedFactorialTriple-blindSupportive care

Summary

This research is intended to begin to explore the impact of inspiratory muscle resistance exercise and/or 1,25(OH)2D3 for improving respiratory muscle strength in cancer patients (subjects).

Timeline

Start
2018-05-25
Primary completion
2020-05-21
Completion
2020-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcitriol Small molecule 0.25 ug Oral

Indications